Bioprocessing - Upstream & Downstream

Biopharma manufacturers have been using the same assays for viral safety testing for decades.

Gene finds that the pressures of viral vector manufacturing are almost too much.

Fail to Prepare? Prepare to Fail…

When EMD Serono wanted to increase drug production, they found that their manufacturing process did not have the required capacity.

As a leading partner and supplier to the industry, MilliporeSigma continues to strengthen and enhance its supply chain capabilities.

Nominations are now open for The Medicine Maker 2020 Power List.

Viral contamination can have devastating effects. But innovations upstream can help prevent that.

ADCs have suffered a few setbacks over the years, but interest in their therapeutic potential – particularly against cancer – remains high.

Innovation in glass continues to be a key enabler for allowing pharma manufacturers to make better, safer products for patients.

Early collaboration and open communication between upstream and downstream are crucial to ensure a consistent end-to-end bioprocess.